Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

COMMD1 as therapeutic target and diagnostic biomarker in NSCLC

April 1, 2021

Sichuan Kelun-Biotech Biopharmaceutical patents nuclear receptor ROR-gamma agonists

April 1, 2021

New Nur77 receptor ligands disclosed by Ixmedicine

April 1, 2021

IMPACT Therapeutics identifies new ATM kinase inhibitors

April 1, 2021

Disulfiram blocks conformational changes of the complex between human p97 and its cofactor Npl4/Ufd1

March 31, 2021

Cabometyx with Opdivo approved in E.U. for first-line advanced RCC

March 31, 2021

Huyabio signs clinical collaboration agreement for phase III melanoma trial of HBI-8000 with Opdivo

March 31, 2021

FDA approves Vyxeos for secondary AML in pediatric patients

March 31, 2021

New SHP-2 inhibitors identified at Sichuan Kelun-Biotech Biopharmaceutical

March 31, 2021

177Lu-DOTA-EB-TATE is well tolerated and effective in patients with late-stage NETs

March 31, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...
GT-02897 exerts efficacy in preclinical multiple myeloma
BioWorld Science
Investigators from the Karl Landsteiner University aimed to evaluate the therapeutic potential of a novel CDK9 inhibitor/degrader, GT-02897, for the potential...